The objective was to determine the reduction of tophi in patients undergoing drug therapy in correlation with urate serum levels through ultrasound examination. A total of 31 male patients, between the ages of 33 to 77 years, with tophaceous gout were evaluated between 2005 and 2009, 11 of which were selected. Ultrasound examinations of visible tophi and evaluations of serum uric acids levels were performed annually on each patient. There was a statistically significant difference between measurements 1, 2, 3 and measurement 4 and between measurements 4 and 5. A strong significant positive association was seen between variation of tophus size and the reduction of serum uric acid levels.
n INTRODUCTION G out is metabolic disease whose clinical manifestations are related to the deposit of monosodium urate crystals in various tissues. When serum uric acid levels are elevated and exceed saturation pH, the uric acid transforms into crystal and is deposited in the tissue (1) . The clinical course of the disease shows periods of arthritis with intermittent asymptomatic periods, known as intercritical periods. In the first stages of the disease, the arthritis is monoarticular and in chronic phases it is oligoarticular or polyarticular of incomplete resolution, with reduction or complete absence of the intercritical period (1) . The presence of tophi is due to inadequate treatment or untreated disease and incorporates monosodium urate crystal deposits, protein matrix and inflammatory cells in tissues (1) . Generally, manifestation of tophi occurs between 5 and 10 years of inadequately treated disease, according to literature. The tophi may be deposited in tendons, ligaments, cartilage, bones and soft tissue, including synovial bursae and pockets, enabling the formation of deformities (1) . Treatment of gout includes the reduction of urate levels, accomplished with the use of synthesis inhibitors (allopurinol, febuxostat) and uricosuric agents (benzbromarone). Allopurinol acts on the xanthine oxidase enzyme, inhibiting the synthesis of uric acid while febuxostat is a non-purine selective inhibitor of santhine oxidase enzyme. Benzbromarone is a uricosuric drug, which reduces the level of uric acid through its increased excretion (2/3 via intestinal and 1/3 via renal). The objective in uric acid reduction therapy is to dissolve the monosodium urate crystals (MSU) crystals when a concentration lower than serum urate saturation is reached There are few studies in the literature, which use ultrasound follow-up in the evaluation of tophi (2) . Ultrasound, which is an easily performed process, is clearly an important tool in the evaluation of tophi during the course of drug therapy for the reduction of gouty tophi.
Objectives
To determine the reduction of tophi in patients with gout undergoing drug therapy; to verify the correlation between the maintenance of appropriate plasma urate levels, that is, below normal/safe values, and the reduction of gout tophi using ultrasound as an imaging method in the evaluation and follow up of tophi measurement. Specific parameters were used for the study of superficial structures, with equipment optimized for musculoskeletal examination. Extended images were obtained in areas with accentuated curvature under the skin in order to facilitate and obtain more precise measurements. Gel was used to provide a good acoustic window and avoid interpositioning of air between the transducer and the skin. The findings were studied and documented in the longitudinal and transversal planes for an adequate characterization of the lesions' limits and adequate gauging. The contralateral side was examined for a comparison with the normal whenever possible. Calculation of tophi volume was carried out using software of the same equipment utilizing the formula (AP×CC×LL×0.523) used to calculate ovoid volumes, considered adequate for the evaluation. n RESULTS The patient's data is shown in Tables I and  Table II shows alteration in gout tophi size. Figure 1 presents the data regarding change in tophus size during the follow-up period. Measurements 1, 2 and 3 were statistically similar and there was a statistically significant reduction between measurements 1, 2, 3 and measurement 4 and between measurement 4 and measurement 5. Therefore it 
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can be concluded that there was a reduction in tophi starting from measurement 4. And, with the ANOVA test, measurements 1, 2, 3 and 4 were statistically similar, the tophi reduction occured from measurement 5. Both tests showed reduction in tophi, from measurements 4 and 5 respectively. This fact is perfectly compatible with clinical results, when a reduction in tophus is verified after a period of regular and daily drug therapy. A correlation between the maintenance of adequate serum urate, that is to say reduction of uric acid levels to below the normal (>7 mg/dL in males) and/or safe levels, and the reduction of tophi volume in patients was verified (Figure 2 An exploratory graph analysis shows that patients who presented a reduction in urate levels during treatment presented an alteration in tophus size different from those who did not show the same reduction. This made it possible to analyse adequately these two subgroups separately. Figure 2 shows the association of size variation in relation to the variation of serum urate and its behaviour in the two aforementioned subgroups. Ultrasound images of the evolution of tophus size in one patient can be observed in Figure 3 .
n DISCUSSION Over the last years there has been growing interest in the use of ultrasound in rheumatology. The advantages include the absence of radiation, low cost, patient cooperation, dynamic multi-plane images, high resolution and an effective method of guiding invasive procedures. 
The physics of ultrasound makes it an ideal tool for the detection of crystaline material in soft tissue. It has long been used in the detection of biliary and urinal calculi, as ultrasound visualizes tissues as acoustic reflections and the crystaline material found in the articulations in cases of gout reflects the sound waves with higher intensity than adjacent tissues such as hyaline cartilage and synovial fluid (19) .
Other methods of imaging may be used in the follow-up of patients with gouty tophi throughout the serum urate reduction therapy. However, not only do they not have all the aforementioned advantages, they also have some disadvantages, such as the use of ionizing radiation, cost and restricted access. Despite the difficulty of finding comprehensive studies on this topic in the literature, the study by Perez-Ruiz et al. (2) shows the validity of ultrasound in the measurement of tophi while carrying out therapeu- 
tic reduction of serum urate, evaluating 50 articulations of 23 patients, comparing the ultrasound results with magnetic resonance. A good correlation was shown between the imaging methods as much in sensitivity and specificity as in correlation between measurements and volume of tophi. Therefore, as an acceptable follow-up method for tophi evaluation, ultrasound was used throughout the period of serum urate reduction treatment. Serum urate reduction treatment has proven to be a good therapeutic instrument in maintaining volume of tophi caused by gout and the follow-up of the volume of these tophi can be assessed by ultrasound, which is a valid, quick and low-cost technique.
n CONCLUSIONS This study shows the reduction of tophi in patient follow-up and the existence of a relationship between the maintenance of adequate plasma uric acid levels and the reduction in volume of tophi using ultrasound imaging as an effective method of evaluation. It has managed to establish a statistically significant relation between the reduction of tophi volume and the serum urate level. 
